Table 1.
Assessment Results for Case 1
| |
Time points relative to ketamine dosing |
|||||||
|---|---|---|---|---|---|---|---|---|
| Assessments | Screen | − 60 min | 60 min | 120 min | Day 2 | Day 4 | Day 8 | Day 15 |
| HRSD17 | 32 | 29 | 16 | 12 | 10 | 10 | 15 | 10 |
| HADS | 25 | 18 | 7 | 2 | 3 | 3 | 9 | 9 |
| HADS-D | 9 | 6 | 5 | 2 | 3 | 1 | 1 | 3 |
| HADS-A | 16 | 12 | 2 | 0 | 0 | 2 | 8 | 6 |
| FIBSER | ∼ | 0 | 0 | 0 | 0 | 7 | 0 | 0 |
| ASC | ∼ | 36 | 18 | 7 | 8 | 11 | 20 | 17 |
| BPRS | ∼ | 53 | 35 | 30 | 34 | 33 | 40 | 34 |
| YMRS | ∼ | 2 | 3 | 1 | 0 | 0 | 0 | 1 |
| MMSE | ∼ | 29 | 30 | 30 | 30 | 30 | 30 | 30 |
| Pain VAS | ∼ | 26 | 17 | 21 | 19 | 6 | 32 | 25 |
HRSD17, hamilton rating scale for depression − 17 item; HADS, hospital anxiety and depression scale; FIBSER, frequency, intensity, and burden of side effects; ASC, adverse symptom checklist; BPRS, brief psychiatric rating scale; YMRS, young mania rating scale; MMSE, mini-mental state exam; Pain VAS, pain visual analogue scale.